Pasotuxizumab (BAY 2010112) is a bispecific T-cell engager (BiTE) targeting PSMA and CD3, designed for the study of metastatic castration-resistant prostate cancer (mCRPC). This antibody exhibits binding affinities with dissociation constants (K_D) of 9.4 nM for human CD3 and 47.0 nM for PSMA, facilitating its dual specificity. Pasotuxizumab is instrumental in engaging T-cells and directing them towards PSMA-expressing prostate cancer cells, making it a valuable tool for advanced prostate cancer research.
Pasotuxizumab (BAY 2010112) is a bispecific T-cell engager (BiTE) targeting PSMA and CD3, designed for the study of metastatic castration-resistant prostate cancer (mCRPC). This antibody exhibits binding affinities with dissociation constants (K_D) of 9.4 nM for human CD3 and 47.0 nM for PSMA, facilitating its dual specificity. Pasotuxizumab is instrumental in engaging T-cells and directing them towards PSMA-expressing prostate cancer cells, making it a valuable tool for advanced prostate cancer research.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
